

The Role of Membrane Phospholipid in Expression of Erythrocyte Rh₀(D) Antigen Activity (40917)

FRED V. PLAPP, MARK M. KOWALSKI, JAMES P. EVANS,
LOWELL L. TILZER, AND MASAHIRO CHIGA

Department of Pathology and Oncology, University of Kansas Medical Center, Kansas City, Kansas 66103

Abstract. Previous investigators have reported that the expression of Rh₀(D) antigen activity by human erythrocytes and their membranes depended on the presence of phospholipid. In order to further elucidate the role of phospholipids in expression of Rh₀(D) antigen activity, erythrocyte membranes and partially purified Rh₀(D) antigens were incubated with bee venom phospholipase A₂. Treatment of erythrocyte membranes with phospholipase A₂ resulted in loss of Rh₀(D) antigen activity as detected by hemagglutination inhibition assays. However, subsequent solubilization of these treated membranes with deoxycholate allowed recovery of Rh₀(D) antigen activity. Phospholipase treatment of solubilized Rh₀(D) antigens, which had been partially purified by affinity chromatography on anti-Rh₀(D) IgG agarose columns, did not destroy Rh₀(D) antigen activity. These results suggested that phospholipids did not affect the antigenic determinants of the Rh₀(D) antigen since solubilized, partially purified Rh₀(D) antigens retained their antigenicity following exposure to phospholipase. Phospholipids were presumably required for proper orientation of Rh₀(D) antigens within erythrocyte membranes since Rh₀(D) membranes lost their antigenicity following phospholipase treatment.

Previous investigators have suggested that the Rh₀(D) antigen present in human erythrocyte membranes is a lipoprotein. This suggestion was based on the observations that removal of phospholipids from erythrocyte membranes by butanol extraction (1, 2) or phospholipases (3) resulted in loss of membrane Rh₀(D) antigen activity. In the former case, Rh₀(D) antigen activity was partially restored by addition of phosphatidylcholine or phosphatidylethanolamine. Thus, these results suggested that phospholipids were necessary for the antigenic activity of membrane-bound Rh₀(D) antigen. More recently, however, our laboratory (4) and others (5) demonstrated that partially purified Rh₀(D) antigen was predominantly protein and was not inactivated by phospholipase (6, 7). These results seemed to indicate that phospholipids were not required for the activity of solubilized Rh₀(D) antigen. In order to investigate this apparent discrepancy between the phospholipid requirements of membrane-bound and solubilized Rh₀(D) antigen, we studied the effect of phospholipase A₂ on the antigenic activity of erythrocyte membranes and solubilized, partially purified Rh₀(D) antigen fractions.

Methods. Erythrocyte membranes were prepared from outdated group O, Rh-positive erythrocytes as previously described (4). Packed membranes were suspended in an equal volume of 0.02 M Tris-HCl (pH 8.0) to give a protein concentration of approximately 4 mg/ml.

Membranes were treated with phospholipase A₂ by adding 200 μ l of membranes, containing 80 μ g of protein, to 1.80 ml of buffer containing 10 mM Hepes (pH 7.4), 148 mM NaCl, and 10 mM CaCl₂. Three units (2 μ g of protein) of bee venom phospholipase A₂ (Sigma) were then added and the suspensions were incubated at 37° for 1 hr. One unit of phospholipase A₂ hydrolyzed 1.0 μ mole of phosphatidylcholine to lysophosphatidylcholine and a fatty acid per minute at pH 8.5 and at 37°. Control membranes were treated identically but without phospholipase. Following incubation, the suspensions were centrifuged at 20,000g for 15 min and the pellets were suspended in 200 μ l of 20 mM Tris-HCl (pH 8.0). In some cases control and phospholipase-treated membranes were solubilized by addition of sodium deoxycholate (Sigma) to a final concentration of 1% (w/v) and incubation for 30 min at room tem-

perature. Solubilized membranes were then centrifuged at 54,000g for 30 min at 4° in a Spinco Type 50 rotor. The supernatants were mixed with 0.2 ml of packed Bio-Beads SM-2 (Bio-Rad) for 1 hr at 25° and the supernatants, which were free of deoxycholate, were recovered following centrifugation at 900g for 2 min.

Membrane phospholipids were extracted by the method of Reed *et al.* (8). Phospholipid, 40 µg in 5 µl of chloroform, was layered onto silica gel K-5 plates (Helena) and chromatographed for 25 min at 25° in a solvent consisting of 38 ml chloroform, 14 ml methanol, and 2 ml of 7.4 N NH₄OH. Phospholipids were visualized by immersing the plates in phosphomolybdic acid (Whatman) for 1 min and heating at 80° for 10 min. The plates were then scanned in a Helena scanning densitometer at 525 nm. Lysophospholipids were not detected by this method.

Rh₀(D) antigens were partially purified from sodium deoxycholate-solubilized Rh-positive membranes by affinity chromatography as previously described (4). Membrane proteins were labeled with fluorescamine (Fluram, Roche) according to Cross and Briggs (9). Sodium dodecyl sulfate–polyacrylamide gel electrophoresis was performed in 5% gels at 8 mA per gel for 90 min according to Fairbanks *et al.* (10). Gels were scanned in a Gilford Model 240 spectrophotometer equipped with a Model 2515 fluorescent gel accessory (11).

The Rh₀(D) antigen activity of membranes and solubilized membrane protein fractions was determined by hemagglutination inhibition assays performed at 37° in rigid microtiter plates with V-shaped wells (Linbro), using papain-treated type O, Rh-positive erythrocytes (4). Rh(c), Rh(E), and LW antigen activities were similarly assayed using papain-treated type O erythrocytes, containing the appropriate Rh or LW antigen, and the appropriate antisera.

The A,B,M, and N activities of erythrocyte membranes were also determined by hemagglutination inhibition assays, except that the assays were performed at 4° and the erythrocytes, containing the appropriate A,B,M, or N antigens, were not treated with papain. In each case 200 µl of mem-

brane fraction were incubated with 50 µl of antisera. All antisera were obtained from Ortho Diagnostics. Complete effacement of wells by erythrocytes indicated hemagglutination, whereas the small button of erythrocytes in the bottom of wells indicated hemagglutination inhibition.

Erythrocyte membrane proteins, which had been solubilized with 1% sodium deoxycholate, were incorporated into liposomes according to Gerritsen *et al.* (12). Two milliliters of deoxycholate solubilized membrane proteins, prepared as described above, were added to 12 mg of egg phosphatidylcholine (Sigma). Following 1 hr of mixing at 25°, 1 ml of Bio-Beads SM-2 was added and the suspension was mixed for another hour. The beads were then removed by centrifugation at 900g for 2 min and the supernatants were centrifuged at 54,000g for 2 hr. The pellets were suspended in 200 µl of phosphate-buffered saline (15 mM Na₂HPO₄, pH 7.4, 0.9% NaCl) and assayed for Rh₀(D) antigen activity.

Results. Incubation of Rh-positive membranes with bee venom phospholipase A₂ resulted in nearly total degradation of phosphatidylcholine, phosphatidylethanolamine, and phosphatidylserine, while sphingomyelin was preserved (Fig. 1). In order to determine the effect of this phospholipid hydrolysis on Rh₀(D) antigen activity, phospholipase-treated membranes were tested by hemagglutination inhibition assay. When Rh-positive erythrocyte membranes were exposed to phospholipase A₂ they did not inhibit the hemagglutination of Rh-positive erythrocytes, indicating the absence of Rh₀(D) antigen activity (Fig. 2b). In contrast, control Rh-positive membranes, which had been incubated under identical conditions, but without phospholipase A₂, inhibited hemagglutination (Fig. 2c), indicating Rh₀(D) antigen activity (4). Thus, phospholipase A₂ appeared to abolish the Rh₀(D) antigen activity of Rh-positive erythrocyte membranes.

Several possibilities exist regarding the mechanism(s) by which phospholipase A₂ abolishes Rh₀(D) antigen activity. Some investigators have reported that various phospholipase preparations contained




FIG. 1. Thin-layer chromatography of phospholipids extracted from untreated (control) erythrocyte membranes (—) and phospholipase-treated erythrocyte membranes (---). PS, phosphatidylserine; S, sphingomyelin; PC, phosphatidylcholine; PE, phosphatidylethanolamine.

contaminating proteases (3), which might have degraded the protein moiety of the Rh₀(D) antigen. On the other hand, if the Rh₀(D) antigen was a lipoprotein, as previously proposed (1–3), it might have been released from the membrane following phospholipid hydrolysis. Alternatively, if the antigenic determinants of the Rh₀(D) antigen were at least partially composed of phospholipids, phospholipase treatment might have diminished the ability of the antigen to bind anti-Rh₀(D) IgG.

In order to determine if the Rh₀(D) antigen had been degraded by contaminating proteases both control and phospholipase-treated membranes were labeled with fluorescamine, solubilized with sodium dodecyl sulfate, and electrophoresed on sodium dodecyl sulfate–polyacrylamide gels. The membrane proteins pattern obtained with control membranes (Fig. 3A) was similar to the pattern described by Fairbanks *et al.* (10). Phospholipase treatment did not affect the membrane protein pattern (Fig. 3B). If proteases had been present they probably would have degraded spectrin bands 1 and 2, since these proteins are very sensitive to proteolysis (13). More definitive evidence that the Rh₀(D) antigen had not been degraded or antigenically altered was obtained by electrophoresis of Rh₀(D) antigen extracts which had been partially purified from control and phospholipase-treated

membranes by affinity chromatography on anti-Rh₀(D) IgG agarose columns (4). As seen in Figs. 3C and D, antigens from both control and treated membranes migrated the same distance, consistent with an approximate molecular weight of 7000, as previously described (4). Thus, the protein moiety of the Rh₀(D) antigen had not been significantly degraded.

In order to determine if phospholipid degradation had resulted in release of the Rh₀(D) antigen from Rh-positive membranes, the supernatants obtained after centrifugation of membrane–phospholipase mixtures were concentrated to the volume of the original membrane suspension and tested by hemagglutination inhibition assays for Rh₀(D) antigen activity. As seen in Fig. 2d no Rh₀(D) antigen activity was detected. When the membrane pellets from the same experiments were solubilized with sodium deoxycholate, which solubilizes the Rh₀(D) antigen (4), much Rh₀(D) antigen activity was recovered (Fig. 2e). The degree of hemagglutination inhibition observed was similar to that obtained with the same quantities of intact control Rh-positive membranes (Fig. 2c) and control membranes solubilized with sodium deoxycholate (Fig. 2f). These results suggested that the Rh₀(D) antigen had not been released from the membrane or degraded to an inactive form since as much antigen activity was recovered from phospholipase-treated membranes as from control membranes.

In order to further demonstrate that the Rh₀(D) antigen, itself, was not affected by phospholipid hydrolysis, partially purified Rh₀(D) antigen was incubated with phospholipase A₂. As seen in Fig. 2j, there was no loss of Rh₀(D) antigen activity compared to partially purified antigen which had not been incubated with phospholipase (Fig. 2i). Also, further evidence that the Rh₀(D) antigen, itself, had not been degraded was established by the finding that the Rh₀(D) antigen, solubilized from phospholipase-treated membranes, could interact with phosphatidylcholine and exhibit Rh₀(D) antigen activity. As seen in Fig. 2g, liposomes containing proteins from phospholipase-treated membranes expressed Rh₀-




FIG. 4. Hemagglutination inhibition assay. Anti-Rh₀(D) IgG was adsorbed with: (a) nothing, (b) untreated (control) erythrocyte membranes, (c) phospholipase-treated erythrocyte membranes, (d) solubilized phospholipase-treated erythrocyte membranes. Anti-Rh(E) IgG was adsorbed with: (e) nothing, (f) untreated (control) erythrocyte membranes, (g) phospholipase-treated erythrocyte membranes, (h) solubilized phospholipase-treated erythrocyte membranes. Anti-LW IgG (Group A Bigelow) was adsorbed with: (i) nothing, (j) untreated (control) erythrocyte membranes, (k) phospholipase-treated erythrocyte membranes, (l) solubilized phospholipase-treated erythrocyte membranes.

membranes by hypotonic lysis (14). Sphingomyelin was not degraded since it is not a substrate for bee venom phospholipase A₂ (14).

Phospholipase treatment of erythrocyte membranes resulted in loss of membrane Rh₀(D) antigen activity which was not due to degradation of antigenic determinants or

release of the antigen from membranes. Instead, these results suggested that intact Rh₀(D) antigen remained bound to the membrane following phospholipase treatment, but could no longer react with anti-Rh₀(D) IgG, until the membrane was solubilized.

These findings could be explained if it is




FIG. 5. Hemagglutination inhibition assay. Anti-A typing sera were adsorbed with: (a) nothing, (b) untreated (control) erythrocyte membranes, (c) phospholipase-treated erythrocyte membranes. Anti-B typing sera were adsorbed with: (d) nothing, (e) untreated (control) erythrocyte membranes, (f) phospholipase-treated erythrocyte membranes. Anti-M typing sera were adsorbed with: (g) nothing, (h) untreated (control) erythrocyte membranes, (i) phospholipase-treated erythrocyte membranes.

assumed that phospholipids did not contribute to the antigenic determinants of the Rh_o(D) antigen, but were required for proper orientation of the antigen within the erythrocyte membrane. Degradation of membrane phospholipids might have altered the native conformation of the Rh_o(D) antigen or the membrane environment necessary for the expression of the antigenic determinants at the outer membrane surface, resulting in the inability of these membranes

to bind antibody. However, following solubilization, deoxycholate might have bound to the Rh_o(D) antigen in place of the degraded phospholipids and allowed the antigen to reassume its active conformation. Similarly, incorporation of solubilized, phospholipase-treated antigen into phosphatidylcholine liposomes would replace the missing phospholipids and allow Rh_o(D) antigen activity.

It was especially intriguing that in the




FIG. 2. Hemagglutination inhibition assay. Anti-Rh₀(D) IgG was adsorbed with the following. Rows (a) nothing, (b) phospholipase-treated erythrocyte membranes, (c) untreated (control) erythrocyte membranes, (d) supernatant after centrifugation of phospholipase-treated membranes, (e) solubilized phospholipase-treated erythrocyte membranes, (f) solubilized untreated erythrocyte membranes, (g) liposomes containing erythrocyte membrane proteins, (h) liposomes containing only egg phosphatidylcholine, (i) partially purified Rh₀(D) antigen, (j) phospholipase-treated partially purified Rh₀(D) antigen, (k) phospholipase-treated membranes incubated with bovine serum albumin.

(D) antigen activity. Phosphatidylcholine alone was not nonspecifically inhibiting hemagglutination since protein-free liposomes did not inhibit agglutination (Fig. 2h).

These results indicated that the Rh₀(D) antigen remained bound to the erythrocyte membrane following phospholipase treatment but could no longer bind anti-Rh₀(D) IgG, until the membrane was solubilized.

Since it has been reported that the free fatty acids released from phospholipids by phospholipase A₂ remained bound to the membrane (14), it seemed possible that these fatty acids might have been bound to the Rh₀(D) antigen and interfered with the antigen-antibody reaction. Therefore, phospholipase-treated membranes were incubated with defatted bovine serum albu-




FIG. 3. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of: (A) 50 μ g of protein from untreated (control) erythrocyte membranes, (B) 50 μ g of protein from phospholipase-treated erythrocyte membranes, (C) 10 μ g of protein from partially purified Rh₀(D) antigen fractions, (D) 10 μ g of protein from partially purified Rh₀(D) antigen fractions treated with phospholipase.

min, which has been shown to extract free fatty acids from phospholipase-treated membranes (14). However, as seen in Fig. 2k, incubation of treated membranes with 2 ml of phosphate-buffered saline containing 6% bovine serum albumin for 1 hr at 37° did not unmask the Rh₀(D) antigen activity.

The effect of phospholipase A₂ on other blood group antigens, besides the Rh₀(D) antigen, was studied to determine if they would also be inactivated. As seen in Fig. 4, incubation of membranes bearing the Rh(c) or Rh(E) antigens with phospholipase A₂ resulted in the loss of these antigen activities (Figs. 4c and g) compared to control membranes (Figs. 4b and f). However, like Rh₀(D) antigen activity, these antigen activities were also recovered following solubilization of phospholipase-treated membranes with sodium deoxycholate (Figs. 4d and h). Similarly, LW antigen activity was abolished by phospholipase A₂ (Fig. 4k), but was recovered following membrane solubilization (Fig. 4l). In contrast, blood groups A, B, and M were not affected by phospholipase A₂ since phospholipase-treated membranes retained as much antigenic activity (Fig. 5c, f, and i) as control membranes (Figs. 5b, e, and h). The N antigen activity of membranes was also not af-

fected by phospholipase (results not shown).

Discussion. Hughes-Jones *et al.* have previously demonstrated that treatment of erythrocyte membranes with phospholipase A₂ resulted in loss of Rh(c), Rh(D), and Rh(e) antigen activities (3). Similarly, Green reported loss of membrane Rh₀(D) antigen activity following extraction of erythrocyte membranes with butanol, which could be partially regenerated by replacing phosphatidylcholine or phosphatidylethanolamine (1, 2). More recently, however, Litten *et al.* (7) and Plapp *et al.* (6) reported that phospholipase A₂ did not effect the activity of purified Rh₀(D) antigen. Our results confirmed these findings and provided a possible explanation for these seemingly conflicting results.

Phospholipase A₂ degraded phosphatidylcholine, phosphatidylethanolamine, and phosphatidylserine (Fig. 1). This pattern of phospholipid hydrolysis was similar to the pattern obtained by Hughes-Jones *et al.* (3). Phospholipase A₂ was able to degrade the aminophospholipids on the inner surface of the erythrocyte membrane, as well as phosphatidylcholine on the outer surface, since it had access to both membrane surfaces following preparation of erythrocyte

membrane-bound state all three of the Rh antigens investigated, as well as the LW antigen, were inactivated by phospholipase A₂ while the A,B and M,N blood group antigens were not affected. The Rh antigens (4-7) and the LW antigen (4) appear to be composed predominantly of protein. However, the A and B antigens are glycolipids (14), while the M and N antigens are glycoproteins (15). In both the A,B and M,N antigenic groups the carbohydrate moieties contribute to antigenic expression. In view of these structural differences, the present results suggested that phospholipids play a more crucial role in maintaining the conformation of protein antigens in the membrane, such as the Rh and LW antigens, than the glycolipid and glycoprotein antigens. Furthermore, these results lend more support to our previous findings of a close structural relationship between the Rh₀(D) antigen and the LW antigen (4).

We thank Dr. Allan N. Williams of Ortho Diagnostics' Blood Bank Research Laboratory for his gift of anti-LW antisera.

3. Hughes-Jones, N. C., Green, E. J., and Hunt, V. A. M., *Vox Sang.* 29, 184 (1975).
4. Plapp, F. V., Kowalski, M. M., Tilzer, L., Brown, P. J., Evans, J., and Chiga, M., *Proc. Nat. Acad. Sci. USA* 76, 2964 (1979).
5. Abraham, C. V., and Bakerman, S., *Clin. Chim. Acta* 60, 33 (1975).
6. Plapp, F. V., Kowalski, M. M., Tilzer, L., and Chiga, M., *Fed. Proc.* 38, 1431 (1979).
7. Litten, J., Culpepper, R., and Bakerman, S., *Biochim. Biophys. Acta* 543, 226 (1978).
8. Reed, C. F., Swisher, S. N., Marinetti, G. V., and Eden, E. G., *J. Lab. Clin. Med.* 56, 281 (1960).
9. Cross, J. W., and Briggs, W. R., *Biochim. Biophys. Acta* 471, 67 (1977).
10. Fairbanks, G., Steck, T. L., and Wallach, D. F. H., *Biochemistry* 10, 2606 (1971).
11. Ragland, W. L., Pace, J. L., and Kemper, D. L., *Anal. Biochem.* 59, 24 (1974).
12. Gerritsen, W. J., Verkley, A. J., Zwaal, R. F. A., and Van Deenen, L. M., *Eur. J. Biochem.* 85, 255 (1978).
13. Marchesi, V. T., *Sem. Hematol.* 16, 3 (1979).
14. Zwaal, R. F. A., Roelofsen, B., and Colley, C. M., *Biochim. Biophys. Acta* 300, 159 (1973).
15. Watkins, W. M., *Proc. R. Soc. Lond. B* 202, 31 (1978).
16. Sadler, J. E., Paulson, J. C., and Hill, R. L., *J. Biol. Chem.* 254, 2112 (1979).

-
1. Green, F. A., *J. Biol. Chem.* 243, 5519 (1968).
 2. Green, F. A., *J. Biol. Chem.* 247, 881 (1972).

Received February 22, 1980. P.S.E.B.M. 1980, Vol. 164.